BAKERSFIELD, CA – The Comprehensive Blood and Cancer Centers, a physician owned and operated organization, has purchased a CyberKnife Robotic Radiosurgery System for its seven-acre campus.

The CyberKnife System, from Sunnyvale, Calif.-based Accuray Inc., is the newest addition to a broad spectrum of technologies and treatments the center offers cancer patients.

CBCC is known as a leader in oncology in the areas of patient care, technology and clinical research. Its facilities treat more than 5,000 new patients per year and have more than 150,000 patient visits annually.

The CyberKnife System will make it possible for physicians to deliver targeted radiosurgery to a tumor located anywhere in the body from virtually unlimited positions. The technology enables the physicians to achieve unprecedented accuracy with sub-millimeter precision thus minimizing damage to surrounding healthy tissue, according to Ravi Patel, MD, founder and chairman of CBCC.

"We have a philosophy and commitment to bringing the most promising treatments and the most sophisticated technology to our community as quickly as possible," Patel said. "The new CyberKnife System will allow us to treat patients who were untreatable in the past. This technology will make a significant difference in the quality of life for our patients and will give CBCC the capability to treat tumors that have previously been inoperable."

"With CBCC's purchase of CyberKnife System, we are increasing the access cancer patients have to cutting-edge treatment technology," said Eric P. Lindquist, senior vice president and chief marketing officer at Accuray.

The CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment, Linquist explained. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.